ArticleMolecular cancer2026
A non-complement role for C1R rewires integrin and death-receptor signaling to drive renal cancer metastasis.
Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundMetastasis is the leading cause of death in clear cell renal cell carcinoma (ccRCC) patients. Anoikis, a form of programmed cell death induced by the loss of cell-extracellular matrix interactions, is a critical factor in hindering metastasis. Nevertheless, the regulatory mechanisms underlying anoikis resistance in ccRCC remain poorly characterized and warrant further investigation.
methodsWe created a single-cell transcriptomic atlas of ccRCC metastasis and used multi-omics data to identify the key role of complement C1R during metastasis. Anoikis-related cell experiments and mouse models were conducted to assess the impact of C1R on anoikis resistance and metastatic potential. Transcriptome sequencing, immunoprecipitation, molecular docking, truncation construction, and immunofluorescence were used to explore how C1R induces anoikis resistance. The mouse lung metastasis model was employed to validate the efficacy of a novel combination drug regimen.
resultsOur study identifies complement C1R as a crucial regulator of ccRCC metastasis by enhancing anoikis resistance. ITGB1 and FAF1 have been recognized as crucial downstream targets of C1R. Specifically, C1R promotes anoikis resistance by facilitating ITGB1 endocytosis to activate the Akt/Erk pathway and by inhibiting FAF1-FAS binding to block the Fas/FasL pathway. Moreover, our findings indicate that the combined use of the ITGB1 inhibitor (ATN161) and the Fas/FasL pathway activator (Edelfosine) significantly suppresses ccRCC metastasis.
conclusionC1R functions as a pivotal driver of ccRCC metastasis through dual mechanisms, and therapeutic strategies targeting C1R may offer a promising approach to inhibit metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.